Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Aclaris Therapeutics (ACRS) over the last 9 years, with Dec 2024 value amounting to $6.7 million.

  • Aclaris Therapeutics' Gains from Investment Securities fell 98.45% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year decrease of 416.51%. This contributed to the annual value of $6.7 million for FY2024, which is 4.71% up from last year.
  • As of FY2024, Aclaris Therapeutics' Gains from Investment Securities stood at $6.7 million, which was up 4.71% from $6.4 million recorded in FY2023.
  • Aclaris Therapeutics' 5-year Gains from Investment Securities high stood at $6.7 million for FY2024, and its period low was $2.9 million during FY2020.
  • For the 3-year period, Aclaris Therapeutics' Gains from Investment Securities averaged around $6.1 million, with its median value being $6.4 million (2023).
  • As far as peak fluctuations go, Aclaris Therapeutics' Gains from Investment Securities declined by 7.44% in 2020, and later soared by 36.25% in 2022.
  • Aclaris Therapeutics' Gains from Investment Securities (Yearly) stood at $2.9 million in 2020, then soared by 32.07% to $3.8 million in 2021, then spiked by 36.25% to $5.2 million in 2022, then rose by 24.24% to $6.4 million in 2023, then grew by 4.71% to $6.7 million in 2024.